Pharma Tariffs and a New Fed Chair: The iShares MSCI World ETF Faces a Summer of Turbulence

iShares MSCI World ETF (URTH) trades just below its 52-week high but faces a hawkish new Fed chair, looming pharmaceutical tariffs, an overbought RSI of 94.6, and rising fee pressure from rivals.

The iShares MSCI World ETF (URTH) is trading at $200.43, barely a dollar below its 52-week peak of $202.74. Yet beneath that placid surface, a succession of high-stakes events — from a hawkish new Federal Reserve chair to an imminent tariff shock on pharmaceuticals — is lining up to test the fund’s resilience. The relative strength index of 94.6 already screams overbought, leaving little room for error.

Kevin Warsh formally took over as Fed chair on May 15 after the Senate confirmed him by the narrowest margin in the central bank’s history, 54 to 45. His first Federal Open Market Committee meeting is scheduled for June 16–17, just one day after the ETF goes ex-dividend. Warsh, a known hawk, wants to shrink the Fed’s balance sheet, reduce the frequency of meetings and inject more unpredictability into policy. With US inflation running at an annual 3.8% — a three-year high that even outpaces wage growth of 3.6% — the market sees a 97% probability of no rate change at the next meeting. Both Bank of America and Goldman Sachs have removed any rate cuts from their 2026 forecasts.

That hawkish turn dovetails with the fund’s structural vulnerability. US equities account for more than 60% of the portfolio, and technology stocks make up nearly 29%. Nvidia is the largest single holding at 5.55%, followed by Apple (4.58%) and Microsoft (3.31%). The top ten positions — including Amazon, Alphabet and Meta — together represent about 27% of assets. The current fed funds rate of 3.50%–3.75%, approved by an unusually split 8–4 vote, leaves these richly valued growth stocks exposed to any further repricing of future earnings.

The macro calendar is dense. On May 29, MSCI’s quarterly index rebalancing takes effect after the close, and a revised free-float methodology kicks in on June 1. New additions include Medline A, MasTec and TechnipFMC, forcing physically replicating funds like URTH to reshuffle holdings and boosting trading volumes around the cutoff. Then, at the end of July, the US plans to introduce a graduated tariff system on imported patented pharmaceuticals. Drugs from the European Union, Japan, South Korea and Switzerland would face a 15% levy; British pharmaceuticals would be hit with 10%. Healthcare makes up roughly one-tenth of URTH’s portfolio, and analysts at FactSet have already trimmed earnings estimates for the sector, warning of an inflationary impulse of about half a percentage point and compressed margins.

Fee competition adds another layer of pressure. Invesco slashed the expense ratio on its rival MSCI World ETF to 0.05% on April 1, widening the gap with URTH’s 0.24% to 19 basis points. BlackRock defends its pricing by pointing to a tracking difference of just 0.02% — the best in class, according to Morningstar, which awards the fund its Gold rating and top star score. The quality argument has held so far: URTH attracted $770 million in net inflows recently.

Beyond the immediate hurdles, a potential SpaceX initial public offering in the second half of 2026 could inject further demand. The rocket company’s valuation is rumored to reach the trillion-dollar range, and Nasdaq rules would permit inclusion in the Nasdaq-100 after just 15 trading days. Analysts estimate index-linked buying could funnel up to $12 billion into the market.

For now, the ETF’s one-year total return stands at 29.14%, with an annualized three-year gain of roughly 20%. The current dividend yield of 1.40% and the ex-dividend date on June 15 will draw income-focused investors. But between Warsh’s debut, the index remix and the looming pharma tariffs, the second half of the year looks far less forgiving.